Incretin Hormones — GLP-1, GIP, the Incretin Effect & Therapeutic Peptides

Incretins are gut-derived peptide hormones released in response to nutrient ingestion that potentiate insulin secretion from pancreatic beta cells. The two principal incretins are GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Together, they account for 50–70% of postprandial insulin secretion — a phenomenon called the incretin effect.

The incretin effect

The observation that oral glucose produces a much larger insulin response than the same glucose load delivered intravenously is called the incretin effect. The difference is entirely attributable to gut hormone release — oral glucose passes through the intestinal epithelium, triggering L-cells (GLP-1) and K-cells (GIP) to release incretin hormones that amplify beta-cell insulin secretion.

In type 2 diabetes, the incretin effect is diminished. GLP-1 response is reduced and GIP-stimulated insulin secretion is impaired. This impairment is a therapeutic target.

GLP-1 (Glucagon-Like Peptide-1)

Source: Intestinal L-cells (ileum, colon)

Structure: 30-amino-acid peptide, processed from proglucagon

Half-life: ~2 minutes (native GLP-1), rapidly degraded by DPP-4

Biological actions:

Potentiates glucose-dependent insulin secretion (only when glucose is elevated — intrinsic safety against hypoglycemia)
Suppresses glucagon secretion from alpha cells
Slows gastric emptying (delays nutrient absorption)
Central appetite suppression (hypothalamic GLP-1 receptor activation)
Potential cardioprotective effects (SELECT trial: 20% MACE reduction with semaglutide)

Therapeutic analogs: The native peptide's 2-minute half-life makes it impractical as a drug. Analogs with DPP-4 resistance and albumin binding extend the half-life dramatically:

Semaglutide — ~168 hours (once-weekly dosing). Fatty acid acylation + amino acid substitutions
Liraglutide — ~13 hours (once-daily dosing)
Exenatide — derived from exendin-4 (Gila monster venom), DPP-4 resistant

GIP (Glucose-Dependent Insulinotropic Polypeptide)

Source: Intestinal K-cells (duodenum, jejunum)

Structure: 42-amino-acid peptide

Half-life: ~5 minutes (native GIP), degraded by DPP-4

Biological actions:

Potentiates glucose-dependent insulin secretion (like GLP-1)
Promotes fat storage in adipose tissue (historically seen as counterproductive)
Bone formation promotion
Potential neuroprotective effects

Therapeutic relevance: GIP's role in obesity therapeutics has been controversial. GIP receptor agonism promotes fat storage in lean individuals but appears to have beneficial effects on body weight when combined with GLP-1 agonism — as demonstrated by tirzepatide.

DPP-4: the incretin terminator

Dipeptidyl peptidase-4 (DPP-4) is a serine protease that cleaves GLP-1 and GIP within minutes of secretion. This rapid degradation is why native incretins cannot be used as drugs and why two therapeutic strategies exist:

Incretin analogs — structurally modified to resist DPP-4 cleavage (semaglutide, tirzepatide, liraglutide)
DPP-4 inhibitors — oral drugs that block DPP-4, raising endogenous incretin levels (sitagliptin, saxagliptin). Less potent than analogs because they only amplify endogenous secretion

Incretin-based therapeutics: the current landscape

|------|--------|-----------|-------------|---------------|

The dual and triple agonist evolution

The field is moving from single-receptor agonism (semaglutide → GLP-1R) to multi-receptor engagement:

Dual agonists (tirzepatide → GLP-1R + GIPR): Greater weight loss and metabolic improvement than single agonists
Triple agonists (retatrutide → GLP-1R + GIPR + glucagon receptor): Phase 2 data shows ~24% weight loss — the highest in the class
Combination approaches (CagriSema → semaglutide + cagrilintide): Combines GLP-1 with amylin analog for complementary satiety signaling

The incretin system's pharmaceutical potential has reshaped metabolic medicine more than any peptide discovery since insulin.